适体
工作流程
计算机科学
灵活性(工程)
计算生物学
人工智能
桥接(联网)
核酸酶
机器学习
管道(软件)
联轴节(管道)
机制(生物学)
计算模型
结构生物学
钥匙(锁)
合成生物学
序列(生物学)
纳米技术
分子构象
作者
Gabriela da Rosa,Mauro de Castro,Víctor Miguel García Velásquez,Santiago Pintos,Jimena Benedetto,Leandro Grille,S Valla,Luis M. Alvarez Salas,Victoria Calzada,Pablo D. Dans
摘要
ABSTRACT Aptamers—short single‐stranded DNA or RNA—are the latest biomolecules to fall within reach of powerful structure‐prediction pipelines that blend bioinformatics, computational chemistry, and artificial intelligence. These tools now enable high‐throughput exploration of aptamer conformational landscapes, a prerequisite for rational design and optimization of their exceptional target affinity and specificity. Next‐generation sequencing has democratized library analysis, allowing any laboratory to handle millions of variants. Hybrid workflows currently offer the most reliable secondary and tertiary structure models, and explicit treatment of conformational flexibility is proving indispensable for mapping binding‐competent states. Yet every predictive tier—from classic free‐energy minimization to deep learning—still underrepresents chemically modified nucleotides, the very substitutions that grant therapeutic aptamers nuclease resistance and pharmacokinetic longevity. Capturing the structural and dynamical consequences of these modifications remains the key unsolved problem. Progress, therefore, hinges on two fronts: richer parameterization and training data that encompass modified bases, and tighter coupling of in silico screens with biophysical and structural validation. Bridging these gaps will convert the current wave of computational advances into clinically relevant aptamer‐based drugs ready to be delivered to the patients. This article is categorized under: Structure and Mechanism > Molecular Structures Data Science > Computer Algorithms and Programming Data Science > Artificial Intelligence/Machine Learning
科研通智能强力驱动
Strongly Powered by AbleSci AI